Insilico Medicine Leaders to Address Global Forums on AI Drug Discovery
Insilico Medicine leadership will present on artificial intelligence commercialization, capital markets, and clinical drug validation across major business and biotechnology ...
Insilico Medicine leadership will present on artificial intelligence commercialization, capital markets, and clinical drug validation across major business and biotechnology ...
Alex Zhavoronkov, CEO of Insilico Medicine, has been named a 2026 Highly Cited Researcher by Clarivate as his firm advances ...
Insilico Medicine will showcase its generative AI drug discovery platforms and automated robotics at upcoming international healthcare and technology conferences ...
A Phase 1 trial presented at ESMO 2026 reports a 40% objective response rate at 130 mg for ISM6331, a ...
Insilico Medicine plans to present first human Phase 1 data for the AI-designed pan-TEAD inhibitor ISM6331 in mesothelioma and other ...
Insilico Medicine's executive team will deliver keynotes and panels at five AI and biopharma conferences in Dubai, Hong Kong, Seoul, ...
Insilico Medicine will present the first clinical data for its AI-designed pan-TEAD inhibitor ISM6331 in a Rapid Oral session at ...
Insilico Medicine executives will speak at premier healthcare and AI summits in New York, Riyadh, Shanghai and Boston this September, ...
In a groundbreaking intersection of artificial intelligence and biotechnology, Insilico Medicine has launched an innovative online platform showcasing the journey ...
Insilico Medicine, a forward-thinking biotechnology company harnessing the power of generative artificial intelligence (AI), has recently confirmed the addition of ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine